Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders Growth (1y) (2014 - 2025)
Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders Growth (1y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.21% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 151.28% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 327.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.59% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 95.87% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -12.04% |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -61.82% |
| Jun 30, 2024 | 73.68% |
| Jun 30, 2023 | -100.00% |
| Sep 30, 2022 | -157.92% |
| Sep 30, 2021 | -99.96% |
| Mar 31, 2021 | -50.38% |
| Dec 31, 2020 | -589.23% |
| Sep 30, 2020 | 3,709,190.91% |
| Jun 30, 2020 | -32,650.00% |
| Mar 31, 2020 | 827.78% |
| Dec 31, 2019 | 2,152.05% |
| Sep 30, 2019 | -101.36% |
| Jun 30, 2019 | -128.57% |
| Mar 31, 2019 | -224.14% |
| Dec 31, 2018 | 1.70% |
| Sep 30, 2018 | -71.12% |
| Jun 30, 2018 | -100.26% |
| Mar 31, 2018 | -99.09% |
| Dec 31, 2017 | -24.49% |
| Sep 30, 2017 | -22.67% |